

November 13, 2025

Company name: ROHTO Pharmaceutical Co., Ltd.

Representative: Hidetoshi Segi,

President and Representative Director

(Code: 4527 TSE Prime)

Contact: Masaya Saito, Vice President and CFO

(TEL: 06-6758-8223)

Notice of Revision of Earnings Forecast and Revision of Dividend Forecast (Dividend Increase)

ROHTO PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that, in light of the recent trends in business performance, the Company has revised its consolidated earnings forecast announced on August 6, 2025, and the Company has revised the year-end dividend announced on May 13, 2025, as described below.

The forecast indicated below is also disclosed in the “Consolidated Financial Results for the Six Months Ended September 30, 2025 [Japanese GAAP].”

1. Revisions to the earnings forecast

(1) Details of the revisions

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A) (Announced on August 6, 2025)	334,500	39,000	43,000	31,500	139.40
Revised forecast (B)	338,500	39,500	44,000	32,000	141.62
Change (B-A)	4,000	500	1,000	500	
Percentage change (%)	1.2	1.3	2.3	1.6	
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2025)	308,625	38,234	39,725	30,841	135.38

(2) Reasons for the revisions

The Company has revised the consolidated financial earnings forecast announced on August 6, as the performance in Japan, Asia, and Americas during first half of fiscal 2025 exceeded expectations, and the second half is also expected to remain strong from the third quarter onwards. Net sales, operating income, ordinary income, and profit attributable to owners of parent are all expected to exceed the previous forecast, resulting in higher sales and profit. The expected exchange rates have been revised to 148 yen per U.S. dollar and 20 yen per Chinese yuan.

*Previous period results are calculated based on figures after retrospective adjustments, reflecting the finalization of the provisional accounting treatment for the business combination conducted in the first quarter of the fiscal year ending March 31, 2026.

2. Revision of Year-end Dividend Forecast.

(1)Details of the revisions

Revision of dividend forecast for the fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

	Dividend per share		
	2nd quarter-end	Year-end	Total
Previous forecast (Announced on May 13,2025)	21.00	21.00	42.00
Revised forecast		22.00	43.00
Current period results	21.00		
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2025)	16.00	20.00	36.00

The Company executed a 2-for-1 stock split of shares of common stock on January 1, 2023.

(2) Reasons for the revisions

Consistently and continually returning to shareholders the profits earned through business activities is one of our highest priorities. The fundamental policy is to pay a dividend based on results of operations. Based on the earnings forecast for the fiscal year ending March 31, 2026 (April 1, 2025 to March 31, 2026), to enhance the return of profits to shareholders, for said fiscal year, the Company has decided to increase the year-end dividend by 1 yen to 22 yen per share. As such, the total annual dividend will be 43 yen per share.

*The above forecasts are based on information available as of the date of announcement. Actual results may differ from the forecasts due to various factors.